FDA Authorise DEKA’s Twiist Insulin Device

DEKA Research & Development’s insulin delivery device, twiist, has received 510(k) authorisation from the US FDA.  

The insulin system was developed to enhance insulin control for individuals aged over six years old and diagnosed with type 1 diabetes.  

Sequel Medical Technologies will spearhead the marketing and sales of the insulin device.   

The system showcases Tidepool Loop innovation, facilitating automated modifications in insulin administration in response to ongoing glucose monitoring data and forecasted glucose readings.  

Alan Lotvin, the head executive at Sequal, stated, “The clearance of the twiist AID system is a pivotal first step in Sequel’s quest to make day-to-day life easier for people with type 1 diabetes.”  

Lotvin went on to add, “The twiist system combines drug delivery technology that directly and precisely measures each dose of insulin, providing the opportunity for better control and flexibility.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.